HUNT VALLEY, Md.--(BUSINESS WIRE)--CepTor Corporation (OTC BB:CEPO), a biopharmaceutical company focusing on cell-targeted therapeutic products for neuromuscular and neurodegenerative diseases, today announced that the results of Neurodur testing in the Experimental Autoimmune Encephalomyelitis (EAE) mouse model, the standard animal model used for MS testing, were published in the Journal of Neuroimmunology. The data indicated that the reduction of clinical symptoms of MS in EAE mice treated with oral Neurodur were statistically significant.
